The incidence of brain metastases is increasing as survival of patients with cancer becomes more prolonged due to advanced cancer therapy. Brain metastases are the most common intracranial tumor; however, brainstem metastases are relatively uncommon, and account for only 3% to 7% of all brain metastases. Open surgery for brainstem metastases is difficult because of the risk of neurological damage. Gamma Knife surgery has been reported to provide benefits to patients with brainstem metastases; however, few data are available to evaluate the effectiveness of GKS for patients with brainstem metastases. In the present study, we review our experience using GKS to treat brainstem metastases.

Methods

Characteristics of Patients

Between September 1995 and December 2008, 32 brainstem metastases in 28 patients were treated with the Leksell Gamma Knife (Elekta AB) at our center. The median age of the patients at the time of GKS for brainstem metastases was 61 years (range 45–83 years). The Karnofsky Performance Scale score ranged from 50% to 100% (median 80%). According to the Radiation Therapy Oncology Group’s Recursive Partitioning Analysis, 23 patients were in Class I, 18 patients were in Class II, and 7 patients were in Class III. The primary malignancies included 22 cases of lung cancer, 5 cases of breast cancer, and 1 case of rectal cancer. Of all 32 lesions, 8 lesions were located in the midbrain, 21 in the pons, and 3 in the medulla oblongata. At the time of GKS, 5 patients presented with a single brainstem metastasis and the other 23 presented with metastatic lesions elsewhere in the brain. Four patients were treated for 2 brainstem metastases. None of the 28 patients had received WBRT previously. Table 1 summarizes clinical characteristics in the 28 patients.

Gamma Knife Surgery

After a local anesthetic agent had been applied to the patient’s head, the stereotactic head frame was af-
fixed. Gadolinium-enhanced T1-weighted MR images, obtained with a slice thickness of 2–3 mm and no gap, were used to determine the target coordinates and treatment planning. The procedure was performed using the Leksell Gamma Knife model B or model C. The median tumor volume was 0.783 cm$^3$ (range 0.03–5.6 cm$^3$). The median tumor margin dose was 16 Gy (range 12–20 Gy), and the median isodose line was 50% (range 45%–90%). We used the GammaPlan system (Elekta AB) for GKS treatment planning. Patients received a single intravenous dose of dexamethasone (5–10 mg) or methylprednisolone (40–80 mg) before GKS.

Follow-Up Examinations

Follow-up MR imaging and clinical examinations were performed every 1–3 months after GKS. Overall survival outcomes were calculated from the date of GKS by using the Kaplan-Meier method.

Follow-up MR images were compared with pre-GKS images. Lesions were measured in the transverse, anteroposterior, and vertical dimensions. Half of the product of these three diameters was used as a surrogate for tumor volume. A complete response was defined as the disappearance of the treated lesion, a partial response as shrinkage of over 50% of the tumor volume, and progressive disease as more than 25% increase of the tumor volume. All else was considered stable disease. Local control was defined as stabilization or improvement of the treated lesion: complete response, partial response, or stable disease.

Results

Survival Time

At the time of the analysis, all patients who had undergone GKS had died. The median survival time was 9 months after GKS (range 2–32 months) (Fig. 1). Survival was 67.9%, 39.3%, and 10.7% at 6 months, 1 year, and 2 years, respectively. The cause of death was documented in all 28 patients. One patient (3.6%) died of recurrent brainstem metastases, and 8 patients (28.6%) died of other non-brainstem metastases (7 patients died of new growth of brain metastases and 1 patient of recurrent non-brainstem metastases). Nineteen patients (67.9%) died of systemic disease progression.

Tumor Control

After GKS, follow-up MR images showed shrinkage of the enhancing lesion in 26 brainstem metastases (81.2%) (a complete response in 7 lesions and a partial response in 19 lesions) and stable disease in 3 brainstem lesions (9.4%). In 3 cases (9.4%), tumor progression was observed at 2, 6, and 10 months. Tumor control in the series was 90.6% (29 of 32 lesions) (Fig. 2).

Complications

A complication was observed in only 1 case (Fig. 3). The patient was a 73-year-old man who harbored a brain-
Gamma Knife surgery for brainstem metastases

A: Before GKS.  B: Three months after GKS.  C: At 3 months after GKS, the brainstem lesion has shrunk.  D: Twelve months after GKS.  E: At 16 months after GKS, the brainstem lesion has disappeared.

Discussion

Brainstem metastases are relatively rare and have been considered lesions that herald a poor prognosis. Surgery is generally not considered for brainstem metastases. In patients with brain metastasis, GKS has been shown to provide excellent local control and survival times. It has been widely accepted that radiosurgical doses for brain metastases range from 15 to 24 Gy in a single treatment. Taking into account that GKS can be more dangerous in patients with brainstem metastases, in our study we delivered a lower prescribed margin dose, ranging from 12 to 20 Gy (median 16 Gy, approximately a 20% dose reduction). Most authors have used lower doses for the treatment of brainstem metastases. The most commonly prescribed median dose for brainstem metastases is 16 Gy, which is consistent with the dose delivered in our study.

Lorenzoni et al. found a correlation between brainstem tumor volume and margin dose: larger lesions are

Fig. 2. Axial Gd-enhanced T1-weighted MR images obtained in a patient with a metastatic lesion in the midbrain; the primary disease in this patient was lung cancer. The lesion was treated radiosurgically with a margin dose of 20 Gy. A: Before GKS. B: Three months after GKS. C: At 3 months after GKS, the brainstem lesion has shrunk. D: Twelve months after GKS. E: At 16 months after GKS, the brainstem lesion has disappeared.

Fig. 3. Axial Gd-enhanced T1-weighted MR images obtained in a patient with a brainstem metastatic lesion in the pons; the primary disease in this patient was also lung cancer. The lesion was treated radiosurgically with a margin dose of 16 Gy. A: Before GKS. B: At 1 month after GKS, the lesion remains stable and peritumoral edema has developed. C: At 4 months after GKS, the brainstem lesion has shrunk and the peritumoral edema has disappeared.
treated with lower prescribed doses. Moreover, Yen et al.11 and Lorenzoni et al.3 noted that the prescribed dose may need to be reduced for patients who have received WBRT previously. In our study, no patients had received WBRT before GKS. In view of the fact that GKS is more dangerous when treating metastases in the medulla oblongata than it is when treating lesions in the pons and midbrain, in this study we treated lesions in the medulla oblongata with a prescribed margin dose of only 12 Gy.

From 1999 to 2011, there were about 9 published studies on GKS for brainstem metastases.1,3,5,7,10 In those studies, the authors reported local control rates ranging from 77% to 100%, median or mean survival times ranging from 4.9 to 12 months, and GKS-related complications ranging from 0% to 11%. Patient outcomes were consistent with results reported for brain metastases in other locations. According to most previous studies, the most important predictor of survival after GKS is the extent and management of extracranial disease; this finding applies not only to brainstem metastases but also to metastases in other brain locations.8

In the present study the median prescribed dose was 16 Gy, the local control rate was 90.6%, and the median survival time was 9 months, all of which are consistent with data from other published series. In the earliest study on GKS for brainstem metastases, Huang et al.3 reported that a median prescribed dose of 16 Gy could achieve a crude local control rate of 95% and a median survival time of 9 months. Yoo et al.11 noted a local tumor control that a median prescribed dose of 16 Gy could achieve a crude local control rate of 95% and a median survival time of 9 months. Hussain et al.4 used a median tumor margin dose of 16 Gy (range 14–23 Gy). Median survival time after GKS was 8.5 months, and local tumor control was achieved in all patients in whom follow-up imaging was conducted.

One complication—peritumoral edema—was observed in only 1 patient in our study. Edema occurred 1 month after GKS and disappeared 4 months after GKS. Complications of GKS for brainstem metastases include the following: intratumoral hemorrhage, radionecrosis, ataxia, vomiting, weakness, dysequilibrium, paresthesia, hemiparesis, and seizures, among others.5,7 Previous studies have reported complication rates ranging from 0% to 11% after GKS for brainstem metastases—rates that are similar to the toxicity of GKS for brain metastases outside the brainstem. However, Grade 3 and 4 toxicities were uncommon in most published studies.

Conclusions

Gamma Knife surgery performed using a median margin dose of 16 Gy is a safe and effective local therapy for patients with brainstem metastases. Brainstem metastases located in the medulla oblongata, those treated with WBRT previously, and those with large tumor volumes should be treated with a lower prescribed margin radiation dose than other lesions.

Disclosure

The authors report no conflict of interest concerning the materials or methods used in this study or the findings specified in this paper.

Author contributions to the study and manuscript preparation include the following. Conception and design: Xu. Acquisition of data: Xu, Li, D Liu, Wang. Analysis and interpretation of data: Xu, Li. Drafting the article: Li. Critically revising the article: all authors. Reviewed submitted version of manuscript: all authors. Approved the final version of the manuscript on behalf of all authors: Xu. Statistical analysis: Li, Zhang. Administrative/technical/material support: Lin. Study supervision: Lin.

References